Protecting brain blood vessels in Alzheimer's disease
Vascular Mechanisms of Dementia: Cell-Type Specific Therapeutic and Imaging Strategies
['FUNDING_R01'] · YALE UNIVERSITY · NIH-10695529
This project tries new treatments and imaging methods aimed at tiny blood-vessel cells to help people with Alzheimer's by reducing iron-related and oxidative damage.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-10695529 on ClinicalTrials.gov |
What this research studies
Researchers aim to develop compounds that specifically target the different cell types in brain blood vessels—endothelial cells, pericytes, and smooth muscle cells—to lower intracellular free iron and harmful reactive oxygen species. They will use laboratory and animal models for proof-of-concept testing of these cell-type specific therapies and will build imaging approaches to see and track vascular cell health in the brain. The team will compare how the compounds protect microvessels and whether imaging can detect early signs of microvascular degeneration such as cerebral amyloid angiopathy, microbleeds, and microinfarcts. Results are intended to guide future clinical work focused on protecting the brain’s blood vessels in people with Alzheimer's and related vascular brain damage.
Who could benefit from this research
Good fit: Ideal candidates would be people diagnosed with Alzheimer's disease or cerebral amyloid angiopathy who might join future trials aimed at protecting small brain blood vessels.
Not a fit: People with dementias that are not driven by vascular problems or those seeking immediate symptom relief from established therapies may not benefit from these early-stage experiments.
Why it matters
Potential benefit: If successful, this work could slow or prevent small-vessel damage in the brain, help preserve blood flow, and potentially slow cognitive decline in Alzheimer's disease.
How similar studies have performed: Prior research links vascular damage and iron/oxidative stress to dementia, but cell-type-specific therapies and targeted vascular imaging like these are largely novel and not yet proven in humans.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GRUTZENDLER, JAIME — YALE UNIVERSITY
- Study coordinator: GRUTZENDLER, JAIME
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease